$112.51
-3.11-2.69%
At Close: -
$112.00
-0.51-0.45%
After Hours: 4:27 PM EDT
15 minutes delayed
Comments
Loading...
Latest news for BioNTech (NASDAQ:BNTX) Stock
BioNTech Stock (NASDAQ: BNTX)
Categories: All
Thursday, September 19, 2024
Wednesday, September 18, 2024
Tuesday, September 17, 2024
Monday, September 16, 2024
- DeSantis Administration Cautions Against Pfizer, Moderna mRNA Covid Vaccines for Vulnerable Individuals, Cites Concerns Related To Rare Heart Conditions
- BioNTech shares are trading higher B of A Sec...
- JP Morgan Upgrades BioNTech to Neutral, Raise...
- B of A Securities Maintains Buy on BioNTech, ...
- HC Wainwright & Co. Reiterates Buy on BioNTec...
Sunday, September 15, 2024
Friday, September 13, 2024
Wednesday, September 11, 2024
Monday, September 09, 2024
Friday, September 06, 2024
Thursday, September 05, 2024
Wednesday, September 04, 2024
Tuesday, September 03, 2024
Thursday, August 29, 2024
Tuesday, August 27, 2024
Monday, August 26, 2024
Friday, August 23, 2024
Thursday, August 22, 2024
Tuesday, August 20, 2024
Monday, August 19, 2024
- FDA Set To Approve COVID-19 Vaccines As Soon As This Week: Stocks, ETFs To Watch
- BioNTech shares are trading higher after the ...
- FDA Allows Resumption Of BioNTech/MediLink Therapeutics Partnered Phase 1 Study For Cancer Drug With Lower Dose
- Unveiling 12 Analyst Insights On BioNTech
- HC Wainwright & Co. Reiterates Buy on BioNTec...
Friday, August 16, 2024
Thursday, August 15, 2024
Tuesday, August 13, 2024
Wednesday, August 07, 2024
Tuesday, August 06, 2024
Monday, August 05, 2024
- US Stocks Trim Black Monday's Drops As Services Gauge Expands, Bond Gains Stall As Traders Reassess Fed Cuts: What's Driving Markets?
- BioNTech's Q2 Loss Widens Amid Low Demand For Its Pfizer-Partnered COVID-19 Vaccine, Increases R&D Spending On New Cancer Products
- Nasdaq, R2K Futures Tumble Over 4%, VIX Spikes Over 100%, Bitcoin Plunges Hard As Global Sell-Off Deepens Amid Recession Fears
- BioNTech Reiterates 2024 Revenues Guidance Of...
- BioNTech Q2 2024 GAAP EPS EUR(3.36) Misses EU...
- Genmab Takes Over Acasunlimab Development, Bi...